RE: The Guardian - "New cancer treatment destroys tumours in terminally ill, finds trial"11 Oct 2021 15:10
"Immunotherapy does not involve chemo so why are we reading about this trial nothing to do with AVA6000 and Avacta"
Because as Rorkes Drift highlights, a key therapeutic target in this study was PD-L1 - Avacta has three (3) programs targeting PD-L1; success in another companies trial in eradicating disease via PD-L1 validates this approach.
The Guardian - "New cancer treatment destroys tumours in terminally ill, finds trial"11 Oct 2021 13:22
A trial at the Royal Marsden has found a ****tail of immunotherapy drugs (antibody-based) has eradicated tumours in some terminally ill patients.
Key takeaway from the piece:
"The results of the trial show the immunotherapy combination enjoyed a particularly high success rate in a group of patients whose tumours had high levels of an immune marker called PD-L1."
Hopefully, this bodes well for Avacta's PD-L1 programs, one of which LG Chem are moving into pre-clinical development.
The researchers state the results "lack statistical significance" but are "clinically meaningful" - perhaps, given the advantages of Affimers over antibodies, Avacta's programs can improve the efficacy of this approach...
It would seem there is indeed still a significant market for LFT's - given supply apparently cannot keep up with demand:
"Travel rule change delayed by lateral flow test shortage
Covid testing firms are facing a shortage of lateral flow tests, says Transport Secretary Grant Shapps.
He told MPs this was the reason for delaying the date when PCR tests will be removed for travellers returning to England.
The travel industry has called on the government to confirm when in October the rules will be changed.
Mr Shapps said it would take several weeks to switch from PCR tests to lateral flow tests.
Addressing the Transport Select Committee, he said the Department of Health was responsible for making the decision.
However, he stressed that his colleagues were aware of school half-term dates and understood the speed required to implement this change.
"But my understanding is that the ramp-up of supply of lateral flow [tests] through the private testing sector has some way to go [since] they have been almost entirely been involved in providing PCR [tests] currently," he told MPs.
When questioned by MP Ben Bradshaw about why this was an issue, since many test providers also offer lateral flow tests, Mr Shapps said it was a question of scale.
"We go from a situation where they are providing a low number of thousands [of tests], to probably millions of tests very quickly and need a few weeks to scale up on it," he said.
He added that the extra few weeks were needed for making sure the administrative switch-over when the rules changed went off without a hitch."
@scaredey - if you control+f "scientific advisory" in the latest annual report it only comes up 5 times: once in relation to governance, the other four in relation to the former director who left the board to chair the scientific advisory board.
Which would support your point that If the SAB barely feature in the annual report and have a largely backroom oversight function, it would make sense to take them off the primary landing page for 'people' in a website reorganisation.
Good spot - looks like trade press as the 'request a quote' email goes to Avacta and the 'about' section says the following:
"LabMedica International meets the need for the international dissemination of the latest techniques and applications in the clinical laboratory field worldwide. Editorial content includes up-to-date news and articles on: Clinical Applications, Scientific Advances, New Products, Technical Literature, and International Events that are of interest to clinical laboratory specialists worldwide. Subjects covered in every issue include: Clinical Chemistry, Immunology, Microbiology, Hematology, Blood-Bank, and Biomedical Research.
Circulation Information: Who Qualifies? LabMedica International is mailed free-of-charge to qualified professionals in hospital and clinical laboratories worldwide (outside the USA and Canada). Circulation includes laboratory directors, clinical chemists, other clinical laboratory specialists, and technologists in these laboratories, as well leading distributors and dealers in the field. To qualify, readers in the above categories must request the publication in writing - by mail, fax or through email.
Publisher Globetech Media is world leader in controlled-circulation international biomedical communications. Current Globetech publications and websites include: HospiMedica International, HospiMedica en Espanol, Medical Imaging International, Lab Medica International, Lab Medica en Espanol, Biotech News International, hospimedica.com, labmedica.com, medimaging.net as well as corresponding websites in various languages."
There's then contacts for the publication in multiple European countries, so presumably it's not just in Spanish.
The 1hr chart on IG suggests 1.5m sold between 9-10am and a gap down in the price, which suggests to me someone bigger than your regular PI dumped a load of shares (maybe these were worked through between 8-9am IDK).
Agree the volume is on the lower side of its average.